Published in Biotech Business Week, February 3rd, 2003
The company expects to report product sales for the fourth quarter of 2002 of approximately $600,000, which would be an increase over the fourth quarter of 2001 of approximately $146,000 or 32%. On a sequential basis, this $600,000 of fourth quarter product sales represents an increase of 26% over third quarter product sales of $477,000.
The company expects to report revenues from the sale of products for 2002 of approximately $1,576,000 as compared to 2001 of $1,461,447. All figures for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.